Loading
The single-arm trial that won eque-cel its approval in China, with almost every patient responding and most reaching deep remissions.
Multicentre single-arm study reported in JAMA Oncology 2024: objective responses in about 96% of infused patients, high rates of stringent complete response and minimal residual disease negativity, durable responses including in patients previously exposed to CAR-T, and mostly grade 1 to 2 cytokine release syndrome. Basis of NMPA approval in June 2023, China's first fully human BCMA CAR-T.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
103 enrolled.
97 of 101 evaluable patients; 103 infused; median follow-up 13.8 months (data cut September 2022)
Source75 of 103 as reported
SourceMedian PFS not reached
SourceGrade 1-2 in 92.3%; ICANS 1.9% (all grade 1-2)
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall response rate (efficacy-evaluable)primary | Equecabtagene autoleucel 1.0 × 10^6 CAR+ T cells/kg | 101 | 96% | - | - | link |
| Complete response or better | Equecabtagene autoleucel | 103 | 74.3% | - | - | link |
| MRD negativity (10^-5) | Equecabtagene autoleucel | - | 95% | - | - | link |
| Progression-free survival at 12 months | Equecabtagene autoleucel | - | 78.8% | - | - | link |
| Cytokine release syndrome, any grade | Equecabtagene autoleucel | 103 | 93.2% | - | - | link |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Equecabtagene autoleucel, Innovent Biologics and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares Innovent Biologics and the tag china.
Shares Innovent Biologics and the tag china.
Shares Innovent Biologics and the tag china.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/